Predicting Intention to Take a COVID-19 Vaccine in the United States: Application and Extension of Theory of Planned Behavior

Am J Health Promot. 2022 May;36(4):710-713. doi: 10.1177/08901171211062584. Epub 2022 Jan 18.

Abstract

Purpose: This study aims to apply and extend the theory of planned behavior (TPB) to predict intention to take a COVID-19 vaccine.

Design: Cross-sectional.

Setting: Online.

Sample: Adult US residents recruited from Amazon Mechanical Turk (n = 172).

Measures: Intention to take a COVID-19 vaccine (outcome variable), demographic variables (predictors), standard TPB variables (perceived behavioral control, attitude, and subjective norm; predictors), and non-TPB variables (anticipated regret, health locus of control, and perceived community benefit; predictors).

Analysis: Hierarchical linear regression predicting intention to take a COVID-19 vaccine, with demographic, standard TPB, and non-TPB variables entered in regression models 1, 2, and 3, respectively.

Results: The extended TPB model accounted for 72.5% of the variance in vaccination intention (p < .001), with perceived behavioral control (β = .29, p < .001), attitude (β = .23, p = .043), and perceived community benefit (β = .23, p = .020) being significant unique predictors.

Conclusion: Despite the relatively small and non-representative sample, this study, conducted after COVID-19 vaccines were widely available in the USA, demonstrated that perceived behavioral control was the most robust predictor of intention to take a COVID-19 vaccine, suggesting that the TPB is a useful theoretical framework that can inform effective strategies to promote vaccine acceptance.

Keywords: COVID-19; perceived behavioral control; perceived community benefits; theory of planned behavior; vaccination intention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Cross-Sectional Studies
  • Humans
  • Intention
  • SARS-CoV-2
  • Surveys and Questionnaires
  • United States

Substances

  • COVID-19 Vaccines